Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer. Surgery is usually curative; however, some locally advanced or metastatic CSCC may be unresectable. Current novel therapeutic options with immune checkpoint inhibition (ICI) of programmed-death receptor 1 (PD-1) such as cemiplimab and nivolumab have demonstrated promising and sustained results with good tolerability in patients with CSCC. This study looks at 2 cases of CSCC treated with cemiplimab and nivolumab, respectively, demonstrating dramatic response within 2 cycles with significant reduction in tumour size and minimal toxicities or adverse outcomes reported. Immunotherapy has shown positive results as an effective treatment option for unresectable, recurrent, or metastatic CSCC. It is currently approved for use in the USA and Europe.

中文翻译：

---

病例系列：Cemiplimab 和 Nivolumab 免疫疗法作为晚期或转移性皮肤鳞状细胞癌的有前景的治疗方法。

皮肤鳞状细胞癌（CSCC）是第二常见的皮肤癌。手术通常可以治愈；然而，一些局部晚期或转移性 CSCC 可能无法切除。目前针对程序性死亡受体 1 (PD-1) 的免疫检查点抑制 (ICI) 的新型治疗选择，例如西米普利单抗和纳武单抗，已在 CSCC 患者中显示出有前景且持续的结果，且具有良好的耐受性。本研究观察了分别用 cemiplimab 和 nivolumab 治疗的 2 例 CSCC 病例，结果显示 2 个周期内出现显着反应，肿瘤大小显着减小，并且报告的毒性或不良结果最小。免疫疗法作为不可切除、复发或转移性 CSCC 的有效治疗选择已显示出积极的结果。目前它已获准在美国和欧洲使用。